Plasma Advanced Glycation End Products Are Associated With Incident Cardiovascular Events in Individuals With Type 2 Diabetes: A Case-Cohort Study With a Median Follow-up of 10 Years (EPIC-NL)
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Experimental data suggest a role for advanced glycation end products (AGEs) in cardiovascular disease (CVD), particularly in type 2 diabetes (T2DM). However, epidemiological evidence of an association between high plasma AGEs and increased cardiovascular risk remains inconclusive. Therefore, in a case-cohort study comprising 134 cardiovascular case subjects and a random subcohort of 218 individuals (including 65 cardiovascular case subjects), all with T2DM and nested in the European Prospective Investigation into Cancer and Nutrition in the Netherlands (EPIC-NL) study, plasma levels of protein-bound Nε-(carboxymethyl)lysine, Nε-(carboxyethyl)lysine, and pentosidine were measured with liquid chromatography. AGEs were loge-transformed, combined in a z-score, and the association with incident cardiovascular events was analyzed with Cox proportional hazard regression, adapted for case-cohort design (Prentice method). After multivariable adjustment (sex, age, cohort status, diabetes duration, total cholesterol to HDL-cholesterol ratio, smoking, systolic blood pressure, BMI, blood pressure–, cholesterol- and glucose-lowering treatment, prior cardiovascular events, and triglycerides), higher plasma AGE z-scores were associated with higher risk of incident cardiovascular events in individuals without prior cardiovascular events (hazard ratio 1.31 [95% CI: 1.06–1.61]). A similar trend was observed in individuals with prior cardiovascular events (1.37 [0.63–2.98]). In conclusion, high plasma AGEs were associated with incident cardiovascular events in individuals with T2DM. These results underline the potential importance of AGEs in development of CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261
Advanced glycation end products and mortality in hemodialysis patients
Schwedler, S. B., Metzger, T., Schinzel, R., & Wanner, C. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00423.x · Cited by 195 · cited 3×
“Indeed, most studies adjusted for BMI (15,16,19,20), but others did not (17,18), and no study adjusted for glucose-, blood pressure–, and cholesterol-lowering medication.”
BackgroundAdvanced glycation endproducts and its receptor for advanced glycation endproducts in obesity
Gaens, K. H., Stehouwer, C. D., & Schalkwijk, C. G. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835aea13 · Cited by 166 · cited 3×
“This is in line with the current concept that AGE accumulation is a complex and heterogeneous process, in which factors such as lipid peroxidation and oxidative stress may play a large role (8), and is not simply dependent on hyperglycemia or decreased renal clearance in diabetes.”
BackgroundSelf-citationKilhovd, B. K., Juutilainen, A., Lehto, S., Rönnemaa, T., Torjesen, P. A., Birkeland, K. I., Berg, T. J., Hanssen, K. F., & Laakso, M. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000158380.44231.fe · Cited by 122 · cited 2×
“Indeed, most studies adjusted for BMI (15,16,19,20), but others did not (17,18), and no study adjusted for glucose-, blood pressure–, and cholesterol-lowering medication.”
BackgroundBusch, M., Franke, S., Wolf, G., Brandstädt, A., Ott, U., Gerth, J., Hunsicker, L. G., & Stein, G. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.07.009 · Cited by 63
van Eupen, M. G. A., Schram, M. T., Colhoun, H. M., Hanssen, N. M. J., Niessen, H. W. M., Tarnow, L., Parving, H. H., Rossing, P., Stehouwer, C. D. A., & Schalkwijk, C. G. (2013) · Diabetologia · doi:10.1007/s00125-013-2919-8 · Cited by 60
Self-citation
Cited by
Advanced Glycation End Products and Oxidative Stress in Type 2 Diabetes Mellitus
Nowotny, K., Jung, T., Höhn, A., Weber, D., & Grune, T. (2015) · Biomolecules · doi:10.3390/biom5010194 · Cited by 1,095
“associated with an increased risk of cardiovascular outcome in T2DM patients [112].”
BackgroundThe role of glutathione reductase and related enzymes on cellular redox homoeostasis network
Couto, N., Wood, J., & Barber, J. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.02.028 · Cited by 1,006
Schalkwijk, C. G., & Stehouwer, C. D. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00001.2019 · Cited by 622
Self-citationWelsh, K. J., Kirkman, M. S., & Sacks, D. B. (2016) · Diabetes Care · doi:10.2337/dc15-2727 · Cited by 207
“Plasma concentrations of CEL, CML, and pentosidine were correlated with incident, but not prior, cardiovascular outcomes in patients with type 2 diabetes (71,72).”
BackgroundRabbani, N., Xue, M., & Thornalley, P. J. (2016) · Clinical Science · doi:10.1042/cs20160025 · Cited by 173
Metadata
- Authors
- Hanssen, N. M. J., Beulens, J. W. J., van Dieren, S., Scheijen, J. L. J. M., van der A, D. L., Spijkerman, A. M. W., van der Schouw, Y. T., Stehouwer, C. D. A., & Schalkwijk, C. G.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-05-21
- Volume
- 64
- Issue
- 1
- Pages
- 257-265
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2115745636
- Cited by
- 156
- References
- 7
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.